Pharma Research Products gains a generic botulinum toxin production company

| By | Drug Manufacturing, GMP Standards, South Korea

Pharma Research Products Company Ltd. (PRP) a Korean company engaged in the development of medical esthetic products announced that it has secured majority ownership of botulinum toxin type A injection (ReNtox) production facility of BioCND, a South Korean venture company. The name of BioCND has been changed to Pharma Research BIO (PR Bio).

The newly acquired company, the PR Bio, has its plant located in the industrial estate at Gangneung-si on the East Coast of South Korea. The newly built modern plant has been designed to meet the Ministry of Food and Drug Safety (the government regulatory agency in South Korea) GMP guidelines. The 6,000 square meter plant has initial capacity of 2 million vials of the ReNtox per year.

Pharma Research Products Ltd. is a South Korean biopharmaceutical company with headquarters in Seongnam-si, Gyeonggi-do. Pharma Research Products Ltd. is on the forefront of research in regenerative medicine in the Republic of Korea and is determined to expand its scope of R&D and manufacturing activities

SOURCE: biospace
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.